Cargando…

Ebola Virus Glycoprotein Domains Associated with Protective Efficacy

Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and the best-characterized virus in the filovirus family. The West African epidemic accelerated the clinical development of vaccines and therapeutics, leading to licensure of vaccines and antibody-based the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatia, Bharti, Furuyama, Wakako, Hoenen, Thomas, Feldmann, Heinz, Marzi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229685/ https://www.ncbi.nlm.nih.gov/pubmed/34200548 http://dx.doi.org/10.3390/vaccines9060630

Ejemplares similares

The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway
por: Furuyama, Wakako, et al.
Publicado: (2021)

The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence In Vivo
por: Groseth, Allison, et al.
Publicado: (2012)

Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection
por: Furuyama, Wakako, et al.
Publicado: (2020)

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
por: Suder, Ellen, et al.
Publicado: (2018)

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
por: Marzi, Andrea, et al.
Publicado: (2016)

Development of an imaging system for visualization of Ebola virus glycoprotein throughout the viral lifecycle
por: Furuyama, Wakako, et al.
Publicado: (2022)

Lack of Protection Against Ebola Virus from Chloroquine in Mice and Hamsters
por: Falzarano, Darryl, et al.
Publicado: (2015)

Cathepsin B & L Are Not Required for Ebola Virus Replication
por: Marzi, Andrea, et al.
Publicado: (2012)

A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection
por: Furuyama, Wakako, et al.
Publicado: (2020)

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
por: Marzi, Andrea, et al.
Publicado: (2015)

Complete Genome Sequences of Three Ebola Virus Isolates from the 2014 Outbreak in West Africa
por: Hoenen, T., et al.
Publicado: (2014)

Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection
por: Furuyama, Wakako, et al.
Publicado: (2016)

Kyasanur Forest Disease and Alkhurma Hemorrhagic Fever Virus—Two Neglected Zoonotic Pathogens
por: Bhatia, Bharti, et al.
Publicado: (2020)

A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades
por: Furuyama, Wakako, et al.
Publicado: (2020)

A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus
por: Bhatia, Bharti, et al.
Publicado: (2021)

Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain
por: Marzi, Andrea, et al.
Publicado: (2015)

Interferon-Induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein
por: Paparisto, Ermela, et al.
Publicado: (2021)

An Upstream Open Reading Frame Modulates Ebola Virus Polymerase Translation and Virus Replication
por: Shabman, Reed S., et al.
Publicado: (2013)

Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses
por: Dunham, Eric C., et al.
Publicado: (2015)

The Ebola Virus Glycoprotein and HIV-1 Vpu Employ Different Strategies to Counteract the Antiviral Factor Tetherin
por: Kühl, Annika, et al.
Publicado: (2011)

Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
por: Blaney, Joseph E., et al.
Publicado: (2013)

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
por: Domi, Arban, et al.
Publicado: (2018)

Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever
por: Marzi, Andrea, et al.
Publicado: (2012)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Effective Chemical Inactivation of Ebola Virus
por: Haddock, Elaine, et al.
Publicado: (2016)

Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat Cells
por: Kühl, Annika, et al.
Publicado: (2011)

Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques
por: Marzi, Andrea, et al.
Publicado: (2023)

A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses
por: Saito, Takeshi, et al.
Publicado: (2020)

Characterization of the catalytic center of the Ebola virus L polymerase
por: Schmidt, Marie Luisa, et al.
Publicado: (2017)

Ebola Virus RNA Editing Depends on the Primary Editing Site Sequence and an Upstream Secondary Structure
por: Mehedi, Masfique, et al.
Publicado: (2013)

Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge
por: Marzi, Andrea, et al.
Publicado: (2019)

Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates
por: Bhatia, Bharti, et al.
Publicado: (2023)

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus
por: Matassov, Demetrius, et al.
Publicado: (2015)

Ebola and Marburg virus vaccines
por: Reynolds, Pierce, et al.
Publicado: (2017)

Ebola sGP—The first viral glycoprotein shown to be C-mannosylated
por: Falzarano, Darryl, et al.
Publicado: (2007)

Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool
por: Hoenen, Thomas, et al.
Publicado: (2016)

Recombinant Antibodies to the Ebola Virus Glycoprotein
por: Panina, A. A., et al.
Publicado: (2017)

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection
por: Qiu, Xiangguo, et al.
Publicado: (2012)

Toremifene interacts with and destabilizes the Ebola virus glycoprotein
por: Zhao, Yuguang, et al.
Publicado: (2016)

Alkhurma haemorrhagic fever virus causes lethal disease in IFNAR(-/-) mice
por: Bhatia, Bharti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hlurcq0rjeu92ob1eai9hri895